Marshall Wace Portfolio holdings
Marshall Wace is a British firm that runs long/short hedge funds. Its strategies combine computer-driven and traditional company analysis, applied worldwide and mostly to long/short equity. Paul Marshall, formerly head of European equities at Mercury Asset Management, and Ian Wace, formerly head of equities trading at Deutsche Bank, founded it in 1997. In 2002 it launched TOPS, a system that gathers investment ideas from equity professionals and uses algorithms to turn them into stock portfolios. In 2015 Marshall Wace formed a long-term partnership with KKR, a private equity and credit investor that took an ownership interest in the firm.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares Core S&P 500 ETF
IVV
|
+$9.9B |
| 2 |
Costco
COST
|
+$907M |
| 3 |
AbbVie
ABBV
|
+$643M |
| 4 |
JPMorgan Chase
JPM
|
+$609M |
| 5 |
Bank of America
BAC
|
+$567M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$1.03B |
| 2 |
Mercado Libre
MELI
|
+$528M |
| 3 |
Broadcom
AVGO
|
+$514M |
| 4 |
Sandisk
SNDK
|
+$507M |
| 5 |
Marvell Technology
MRVL
|
+$499M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 34.91% |
| 2 | Technology | 20.64% |
| 3 | Consumer Discretionary | 9.1% |
| 4 | Healthcare | 8.21% |
| 5 | Financials | 7.4% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
3151
PUT
KE Holdings
BEKE
$19B
| – | – |
-2,200
| Closed | -$32.9K | – |
|
3152
Franklin Templeton
BEN
$16.1B
| – | – |
-757,036
| Closed | -$17.9M | – |
|
3153
Bar Harbor Bankshares
BHB
$680M
| – | – |
-48,619
| Closed | -$1.58M | – |
|
3154
CALL
Baidu
BIDU
$27.1B
| – | – |
-200
| Closed | -$22.3K | – |
|
3155
CALL
Bilibili
BILI
$5.33B
| – | – |
-2,800
| Closed | -$63.2K | – |
|
|
3156
Bilibili
BILI
$5.33B
| – | – |
-13,998
| Closed | -$316K | – |
|
|
3157
PUT
Bilibili
BILI
$5.33B
| – | – |
-1,900
| Closed | -$42.9K | – |
|
3158
Bioceres Crop Solutions
BIOX
$15.9M
| – | – |
-702,478
| Closed | -$309K | – |
|
3159
PUT
Bank of New York Mellon
BNY
$100B
| – | – |
-100
| Closed | -$11.9K | – |
|
3160
BK Technologies
BKTI
$271M
| – | – |
-15,964
| Closed | -$1.19M | – |
|
3161
REalloys Inc
ALOY
$510M
| – | – |
-447,464
| Closed | -$4.37M | – |
|
3162
Blackbaud
BLKB
$2.37B
| – | – |
-19,577
| Closed | -$756K | – |
|
3163
Broadstone Net Lease
BNL
$3.3B
| – | – |
-194,855
| Closed | -$3.56M | – |
|
3164
Benitec Biopharma
BNTC
$307M
| – | – |
-71,832
| Closed | -$765K | – |
|
3165
CALL
BioNTech
BNTX
$22.1B
| – | – |
-2,900
| Closed | -$258K | – |
|
|
3166
PUT
BioNTech
BNTX
$22.1B
| – | – |
-2,500
| Closed | -$222K | – |
|
3167
PUT
Berkshire Hathaway Class B
BRK.B
$1.16T
| – | – |
-300
| Closed | -$144K | – |
|
3168
Streamex Corp
STEX
$48.2M
| – | – |
-536,920
| Closed | -$607K | – |
|
3169
CALL
Boston Scientific
BSX
$61.5B
| – | – |
-100
| Closed | -$6.28K | – |
|
3170
B2Gold
BTG
$6.76B
| – | – |
-87,800
| Closed | -$398K | – |
|
3171
Bioventus
BVS
$1B
| – | – |
-103,528
| Closed | -$945K | – |
|
3172
Broadwind
BWEN
$76.6M
| – | – |
-297,451
| Closed | -$619K | – |
|
3173
Byrna Technologies
BYRN
$109M
| – | – |
-141,591
| Closed | -$1.3M | – |
|
3174
Credit Acceptance
CACC
$5.66B
| – | – |
-6,183
| Closed | -$2.62M | – |
|
3175
CACI
CACI
$14.7B
| – | – |
-14,977
| Closed | -$8.15M | – |
|
Similar funds
Marshall Wace's Q2 2026 Portfolio in Review
As of Q2 2026, Marshall Wace held 3,898 positions worth $127B, up 26% from $100B the previous quarter. Its ten largest holdings account for 38% of the portfolio.
Marshall Wace deployed $9.28B of net new capital in Q2 2026, opening 771 new positions and adding to 1,083 existing holdings. Its largest new stake was LPL Financial: 975,627 shares worth $275M.
By sector, the portfolio is most concentrated in Miscellaneous at 35% of assets, up from 30% a quarter earlier, followed by Technology and Consumer Discretionary.
On the sell side, the largest reduction was NVIDIA, an estimated $1.03B trimmed.
- Marshall Wace's largest Q2 2026 buy was LPL Financial: 975,627 shares worth $275M.
- Marshall Wace added most to iShares Core S&P 500 ETF in Q2 2026, an estimated $9.9B increase.
- Marshall Wace's biggest Q2 2026 reduction was NVIDIA, cutting an estimated $1.03B.
- Marshall Wace fully exited Merck in Q2 2026, selling an estimated $325M.
- Marshall Wace's ten largest holdings make up 38% of its $127B portfolio in Q2 2026.
- Marshall Wace opened 771 new positions and closed 795 in Q2 2026.
- Marshall Wace's portfolio value rose 26% quarter-over-quarter to $127B.
Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.